Prof. Dr. Johannes von Kempis
Rheumatologie · Dept. I
Worse cardiovascular and renal outcome in male SLE patients.
Mihailovic J, Ribi C, Chizzolini C, Trendelenburg M, von Kempis J, Dahdal S, Huynh-Do U, Swiss Systemic Lupus Erythematosus Cohort Study Group (SSCS). Worse cardiovascular and renal outcome in male SLE patients. Sci Rep 2023; 13:18628.
Oct 30, 2023Worse cardiovascular and renal outcome in male SLE patients.
Oct 30, 2023Sci Rep 2023; 13:18628
Mihailovic Jelena, Ribi Camillo, Chizzolini Carlo, Trendelenburg Marten, von Kempis Johannes, Dahdal Suzan, Huynh-Do Uyen, Swiss Systemic Lupus Erythematosus Cohort Study Group (SSCS)
Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care.
Riek M, Scherer A, Möller B, Ciurea A, Von Mühlenen I, Gabay C, Kyburz D, Brulhart L, von Kempis J, Mueller R, Hasler P, Strahm T, von Känel S, Zufferey P, Dudler J, Finckh A. Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care. Sci Rep 2023; 13:17776.
Oct 18, 2023Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care.
Oct 18, 2023Sci Rep 2023; 13:17776
Riek Myriam, Scherer Almut, Möller Burkhard, Ciurea Adrian, Von Mühlenen Ines, Gabay Cem, Kyburz Diego, Brulhart Laure, von Kempis Johannes, Mueller Ruediger B, Hasler Paul, Strahm Tanja, von Känel Sabine, Zufferey Pascal, Dudler Jean, Finckh Axel
Anti-interleukin-23 directed therapy and the recurrence of severe allergic asthma
Schmiedeberg K, Rassouli F, von Kempis J, Rubbert-Roth A. Anti-interleukin-23 directed therapy and the recurrence of severe allergic asthma. Rheumatology (Oxford) 2022
Feb 8, 2022Anti-interleukin-23 directed therapy and the recurrence of severe allergic asthma
Feb 8, 2022Rheumatology (Oxford) 2022
Schmiedeberg Kristin, Rassouli Frank, von Kempis Johannes, Rubbert-Roth Andrea
Postvaccination anti-S IgG levels predict anti-SARS-CoV-2 neutralising activity over 24 weeks in patients with RA.
Schmiedeberg K, Abela I, Pikor N, Vuilleumier N, Schwarzmueller M, Epp S, Pagano S, Grabherr S, Patterson A, Nussberger M, Trkola A, Ludewig B, von Kempis J, Rubbert-Roth A. Postvaccination anti-S IgG levels predict anti-SARS-CoV-2 neutralising activity over 24 weeks in patients with RA. RMD Open 2022; 8
Jan 1, 2022Postvaccination anti-S IgG levels predict anti-SARS-CoV-2 neutralising activity over 24 weeks in patients with RA.
Jan 1, 2022RMD Open 2022; 8
Schmiedeberg Kristin, Abela Irene A, Pikor Natalia, Vuilleumier Nicolas, Schwarzmueller Magdalena, Epp Selina, Pagano Sabrina, Grabherr Sarah, Patterson Angelica Brooke, Nussberger Madalina, Trkola Alexandra, Ludewig Burkhard, von Kempis Johannes, Rubbert-Roth Andrea
Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel).
Mueller R, Schulze-Koops H, Furst D, Cohen S, Kwok K, Wang L, Killeen T, von Kempis J. Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel). Clin Rheumatol 2022; 41:1045-1055.
Jan 1, 2022Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel).
Jan 1, 2022Clin Rheumatol 2022; 41:1045-1055
Mueller Ruediger B, Schulze-Koops Hendrik, Furst Daniel E, Cohen Stanley B, Kwok Kenneth, Wang Lisy, Killeen Tim, von Kempis Johannes
Anti-S1 Antibodies After Vaccination with Anti SARS-CoV-2 mRNA Vaccines in Patients with Rheumatoid Arthritis Differ in Magnitude and Kinetics from Healthy Controls: Results from a Prospective, Observational Controlled Study
Rubbert-Roth A, Vuilleumier N, Ludewig B, Schmiedeberg K, Rottländer Y, Pirker I, von Kempis J (2022). Anti-S1 Antibodies After Vaccination with Anti SARS-CoV-2 mRNA Vaccines in Patients with Rheumatoid Arthritis Differ in Magnitude and Kinetics from Healthy Controls: Results from a Prospective, Observational Controlled Study.
Dec 28, 2021Anti-S1 Antibodies After Vaccination with Anti SARS-CoV-2 mRNA Vaccines in Patients with Rheumatoid Arthritis Differ in Magnitude and Kinetics from Healthy Controls: Results from a Prospective, Observational Controlled Study
Dec 28, 2021ACR Converence 2021
Rubbert-Roth Andrea, Vuilleumier Nicolas, Ludewig Burkhard, Schmiedeberg Kristin, Rottländer Yella, Pirker Ian, von Kempis Johannes
Anti-SARS-CoV-2 mRNA vaccines as inducers of humoral response against apolipoprotein A-1?
Vuilleumier N, Pagano S, Ludewig B, Schmiedeberg K, Haller C, von Kempis J, Rubbert-Roth A. Anti-SARS-CoV-2 mRNA vaccines as inducers of humoral response against apolipoprotein A-1?. Eur J Clin Invest 2021; 52:e13713.
Nov 29, 2021Anti-SARS-CoV-2 mRNA vaccines as inducers of humoral response against apolipoprotein A-1?
Nov 29, 2021Eur J Clin Invest 2021; 52:e13713
Vuilleumier Nicolas, Pagano Sabrina, Ludewig Burkhard, Schmiedeberg Kristin, Haller Christoph, von Kempis Johannes, Rubbert-Roth Andrea
Treatment of refractory subacute cuataneous lupus erythematosus with baricitinib
Joos L, Vetterli F, Jaeger T, Cozzio A, von Kempis J, Rubbert-Roth A. Treatment of refractory subacute cuataneous lupus erythematosus with baricitinib. Clin Exp Dermatol 2021
Nov 8, 2021Treatment of refractory subacute cuataneous lupus erythematosus with baricitinib
Nov 8, 2021Clin Exp Dermatol 2021
Joos L, Vetterli F, Jaeger T, Cozzio A, von Kempis Johannes, Rubbert-Roth Andrea
Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses
Schmiedeberg K, Vuilleumier N, Pagano S, Albrich W, Ludewig B, von Kempis J, Rubbert-Roth A. Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses. Lancet Rheumatol 2021; 4:e11-e13.
Oct 26, 2021Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses
Oct 26, 2021Lancet Rheumatol 2021; 4:e11-e13
Schmiedeberg Kristin, Vuilleumier Nicolas, Pagano Sabrina, Albrich Werner, Ludewig Burkhard, von Kempis Johannes, Rubbert-Roth Andrea
Successful Treatment of Rituximab-Associated Palmoplantar Pustulosis With Apremilast in a Patient With Seropositive Rheumatoid Arthritis
Haller C, Cozzio A, von Kempis J, Rubbert-Roth A. Successful Treatment of Rituximab-Associated Palmoplantar Pustulosis With Apremilast in a Patient With Seropositive Rheumatoid Arthritis. J Clin Rheumatol 2021; 27:e289-e290.
Oct 1, 2021Successful Treatment of Rituximab-Associated Palmoplantar Pustulosis With Apremilast in a Patient With Seropositive Rheumatoid Arthritis
Oct 1, 2021J Clin Rheumatol 2021; 27:e289-e290
Haller Christoph, Cozzio Antonio, von Kempis Johannes, Rubbert-Roth Andrea
Clinical Image: In vivo urate spherulites in a patient with gout
Pirker I, Nussberger M, von Kempis J. Clinical Image: In vivo urate spherulites in a patient with gout. ACR Open Rheumatol 2021; 3:888.
Sep 23, 2021Clinical Image: In vivo urate spherulites in a patient with gout
Sep 23, 2021ACR Open Rheumatol 2021; 3:888
Pirker Ian, Nussberger Madalina, von Kempis Johannes
Pausing drugs and spacing vaccines: an open question - Authors' reply
Rubbert-Roth A, Schmiedeberg K, von Kempis J. Pausing drugs and spacing vaccines: an open question - Authors' reply. Lancet Rheumatol 2021; 3:e683-e684.
Sep 22, 2021Pausing drugs and spacing vaccines: an open question - Authors' reply
Sep 22, 2021Lancet Rheumatol 2021; 3:e683-e684
Rubbert-Roth Andrea, Schmiedeberg Kristin, von Kempis Johannes
Variants Affecting the C-Terminal Tail of UNC93B1 Are Not a Common Risk Factor for Systemic Lupus Erythematosus
Kiener S, Ribi C, Keller I, Chizzolini C, Trendelenburg M, Huynh-Do U, von Kempis J, On Behalf Of Swiss Sle Cohort Study Sscs, Leeb T. Variants Affecting the C-Terminal Tail of UNC93B1 Are Not a Common Risk Factor for Systemic Lupus Erythematosus. Genes (Basel). 2021; 12
Aug 19, 2021Variants Affecting the C-Terminal Tail of UNC93B1 Are Not a Common Risk Factor for Systemic Lupus Erythematosus
Aug 19, 2021Genes (Basel). 2021; 12
Kiener Sarah, Ribi Camillo, Keller Irene, Chizzolini Carlo, Trendelenburg Marten, Huynh-Do Uyen, von Kempis Johannes, On Behalf Of Swiss Sle Cohort Study Sscs, Leeb Tosso
Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis
Rubbert-Roth A, Vuilleumier N, Ludewig B, Schmiedeberg K, Haller C, von Kempis J. Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis. Lancet Rheumatol 2021; 3:e470-e472.
Jun 8, 2021Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis
Jun 8, 2021Lancet Rheumatol 2021; 3:e470-e472
Rubbert-Roth Andrea, Vuilleumier Nicolas, Ludewig Burkhard, Schmiedeberg Kristin, Haller Christoph, von Kempis Johannes
Analysis of patients with rheumatoid arthritis and higher radiographic progression: association of very high radiographic progression but not of intermediately high worsening of patient-related outcomes
Thalmann R, von Kempis J, Zgraggen A, Schiff M, Sokka T, Dietrich T, Schulze-Koops H, Mueller R. Analysis of patients with rheumatoid arthritis and higher radiographic progression: association of very high radiographic progression but not of intermediately high worsening of patient-related outcomes. Clin Exp Rheumatol 2021
May 5, 2021Analysis of patients with rheumatoid arthritis and higher radiographic progression: association of very high radiographic progression but not of intermediately high worsening of patient-related outcomes
May 5, 2021Clin Exp Rheumatol 2021
Thalmann Reto, von Kempis Johannes, Zgraggen Armin, Schiff Michael, Sokka Tuulliki, Dietrich Tobias, Schulze-Koops Hendrik, Mueller Ruediger B
Clinical Images: Hydroxychloroquine-associated mucous labial pigmentation in a patient with systemic lupus erythematosus improving under topical treatment with tacrolimus
Pirker I, Saulite I, von Kempis J. Clinical Images: Hydroxychloroquine-associated mucous labial pigmentation in a patient with systemic lupus erythematosus improving under topical treatment with tacrolimus. ACR Open Rheumatol 2021; 3:41.
Jan 3, 2021Clinical Images: Hydroxychloroquine-associated mucous labial pigmentation in a patient with systemic lupus erythematosus improving under topical treatment with tacrolimus
Jan 3, 2021ACR Open Rheumatol 2021; 3:41
Pirker Ian, Saulite Ieva, von Kempis Johannes
Real-World Effectiveness of Belimumab in the Treatment of Systemic Lupus Erythematosus: Pooled Analysis of Multi-Country Data from the OBSErve Studies
Collins C, Cortes-Hernández J, Garcia M, von Kempis J, Schwarting A, Touma Z, Kurtinecz M, Gairy K. Real-World Effectiveness of Belimumab in the Treatment of Systemic Lupus Erythematosus: Pooled Analysis of Multi-Country Data from the OBSErve Studies. Rheumatol Ther 2020; 7:949-965.
Nov 18, 2020Real-World Effectiveness of Belimumab in the Treatment of Systemic Lupus Erythematosus: Pooled Analysis of Multi-Country Data from the OBSErve Studies
Nov 18, 2020Rheumatol Ther 2020; 7:949-965
Collins Christopher E, Cortes-Hernández Josefina, Garcia Mercedes A, von Kempis Johannes, Schwarting Andreas, Touma Zahi, Kurtinecz Milena, Gairy Kerry
Real-World Effectiveness of Belimumab in the Treatment of Systemic Lupus Erythematosus: Pooled Analysis of Multi-Country Data from the OBSErve Studies
Collins C, Cortes-Hernandez J, Garcia M, von Kempis J, Schwarting A, Touma Z, Kurtinecz M, Gairy K. Real-World Effectiveness of Belimumab in the Treatment of Systemic Lupus Erythematosus: Pooled Analysis of Multi-Country Data from the OBSErve Studies. Rheumatology and Therapy 2020; 7:949-965.
Nov 18, 2020Real-World Effectiveness of Belimumab in the Treatment of Systemic Lupus Erythematosus: Pooled Analysis of Multi-Country Data from the OBSErve Studies
Nov 18, 2020Rheumatology and Therapy 2020; 7:949-965
Collins C.E., Cortes-Hernandez J, Garcia M.A., von Kempis Johannes, Schwarting A, Touma Z, Kurtinecz M, Gairy K
Tocilizumab in a patient with newly diagnosed rheumatoid arthritis secondary to checkpoint inhibitor therapy
Pirker I, Rubbert-Roth A, von Kempis J, Fehr M, Neumann T. Tocilizumab in a patient with newly diagnosed rheumatoid arthritis secondary to checkpoint inhibitor therapy. Clin Exp Rheumatol 2020
Jan 28, 2020Tocilizumab in a patient with newly diagnosed rheumatoid arthritis secondary to checkpoint inhibitor therapy
Jan 28, 2020Clin Exp Rheumatol 2020
Pirker Ian, Rubbert-Roth Andrea, von Kempis Johannes, Fehr Martin, Neumann Thomas
Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau Cohorts
Mueller R, Schulze-Koops H, Rubbert-Roth A, Hasler P, Souza A, Durmisi M, Mattow F, Popp F, Hasler C, von Kempis J. Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau Cohorts. J Clin Med 2019; 8
Sep 26, 2019Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau Cohorts
Sep 26, 2019J Clin Med 2019; 8
Mueller Ruediger B, Schulze-Koops Hendrik, Rubbert-Roth Andrea, Hasler Paul, Souza Alexander, Durmisi Mirsada, Mattow Frederik, Popp Florian, Hasler Caroline, von Kempis Johannes